Identifying novel targets for cancer immunotherapy
Exploiting the power of machine learning and structural modelling
Applying machine learning and structural modelling technology to develop TCR(like) therapies with no cross-reactivity.
Neoantigens
Cancer-specific antigens expressed by almost all tumor types.
TCR(like) therapies
An effective & scalable way to target neoantigens.
No cross-reactivity
Imuno’s technology enables the development of fully specific anti-cancer therapies.
Neoantigens
What if we could visualise how mutations change the surface of cancer cells? Explore what makes them distinct? It would enable us to identify unique targets and best-in-class therapies.
At Imuno we broaden the repertoire of cancer-specific antigens to lay the foundation for novel therapies. We are building a best-in-class machine learning platform to identify novel targets and engineer safe and effective therapies.
Our platform
Target identification
Structural modelling
Cross-reactivity
Cross-reactivity prediction
Laboratory validation
Drug development
Accurate cross-reactivity prediction
We have built a structure-based discovery engine to identify cancer-specific epitopes that can be exploited by novel therapeutic strategies. Our discovery engine identifies potential cross-reactive epitopes, providing a cohesive link with conventional in-vitro safety studies. It delivers missing information and better guidance to develop safe therapies.
Imuno's platform has several unique advantages
More accurate and faster than conventional cross-reactivity screening methods
Integration of gene expression, proteasomal cleavage and peptide-HLA affinity
Ability to screen cross-reactivity for any cell type (full coverage of proteome)
The future is
precision therapy!
Neoantigen
Self-peptides
But
TCR(like) therapies may cross-react with self-peptides and induce toxicity
The Team
Providing benefit for oncology patients is a challenge. But we are motivated to make a difference. It is our mission to engineer precision therapies for patients with hard to treat cancers by exploiting the power of machine learning.
Roberto
Fornelino
DATA SCIENTIST
Roberto makes sure our neoantigens take on the right conformation and identifies which are unique. Trained as biologist and data scientist, Roberto has worked in the field of neoantigen discovery.
New office
Winter 2022
Simona Aufiero
HEAD BIOINFORMATICS
Simona makes sure our platforms keeps improving by defining the right AI-based strategies for neoantigen target discovery and valdiation. She holds a PhD from the University of Amsterdam.
Joanna Turley
SENIOR SCIENTIST
Joanna designs experiments to create and assess Imuno’s neoantigen-targeting drugs. She previously worked in infectious disease and cancer vaccinology and holds a PhD in Immunology from Trinity College Dublin.
Antibody development
Winter 2022
Launch of version 2.0
Summer 2022
Jan-JaapVerhoef
CEO
Jan-Jaap makes sure the team has great coffee and that everyone is as motivated as possible to realise our mission.